Daniel J. Lippis - 10 Mar 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, JAPAC
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
10 Mar 2025
Net transactions value
-$9,681
Form type
4
Filing time
10 Mar 2025, 19:34:07 UTC
Previous filing
18 Feb 2025
Next filing
08 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $18,111 +400 +1.8% $45.28 22,988 10 Mar 2025 Direct F1
transaction EW Common Stock Sale $27,792 -400 -1.7% $69.48 22,588 10 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -400 -39% $0.000000 630 10 Mar 2025 Common Stock 400 $45.28 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.